Explore more price target data and ratings for Collegium Pharmaceutical, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Collegium Pharmaceutical, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Sy…
Q2 2026 saw strong ADHD portfolio growth, with JORNAY PM and AZSTARYS driving revenue gains and market share, while pain portfolio revenues were mixed due to pricing pressures. Full-year guidance was raised for AZSTARYS, and capital deployment remains disciplined.Based on Collegium Pharmaceutical…
Q2 2026 saw 6% revenue growth and 8% adjusted EBITDA growth year-over-year, driven by strong ADHD and pain portfolio performance and the successful integration of AZSTARYS. Updated 2026 guidance projects $825–855M in revenue and $445–470M in adjusted EBITDA.Original document: Collegium Pharmaceutic…
Collegium Pharmaceutical reported second-quarter 2026 results with product revenue rising to $199.88M versus $188M a year earlier, while net loss widened to ($15.05M) and diluted EPS was ($0.46) as acquisition-related and commercial expansion costs increased — 10-Q Summary.Financial Highlights¹ Rep…
Pharmaceutical company Collegium Pharmaceutical NASDAQ:COLLwill be reporting results this Thursday before market open. Here’s what to look for.Collegium Pharmaceutical beat analysts’ revenue expectations last quarter, reporting revenues of $193.5 million, up 8.9% year on year. It was a mixed quarte…
